10-K: Adverum Biotechnologies Faces Going Concern Doubt Amidst Restatement and Financial Challenges

Adverum Biotechnologies' 10-K filing reveals substantial doubt about its ability to continue as a going concern due to recurring losses, a material weakness in internal controls, and the need for additional funding.

Summary

• Adverum Biotechnologies' 10-K filing indicates substantial doubt about the company's ability to continue as a going concern.
• This is due to recurring operating losses, a material weakness in internal control over financial reporting, and the need to raise substantial additional funding.
• The company's cash, cash equivalents, and short-term investments totaled $125.7 million as of December 31, 2024, expected to fund operations into the second half of 2025.
• A restatement of previously issued financial statements was required due to non-cash errors in accounting for tenant improvement allowances related to a North Carolina property.
• The company is actively pursuing additional funding through various means, including equity and debt financing, collaborations, and licensing arrangements.
• Adverum is focused on advancing its lead product candidate, Ixo-vec, through Phase 3 clinical trials for wet AMD.
• The company is also developing an early-stage pipeline of gene therapy programs targeting other ocular diseases.
• The company faces intense competition in the biopharmaceutical industry, including from companies with greater resources and experience.
• The company is subject to extensive regulation and compliance requirements, which could cause delays or prevent the receipt of required approvals.
• The company is dependent on key executives and clinical and scientific staff, and may encounter difficulties in managing growth and expanding operations successfully.

Sentiment

Score: 3

Explanation: The document presents a concerning financial outlook with a going concern warning, a restatement due to internal control issues, and the need for additional funding. While there are positive aspects like ongoing clinical trials and a pipeline, the overall tone is negative due to the financial instability and operational challenges.

Positives

• Ixo-vec is advancing through Phase 3 clinical trials for wet AMD.
• The company is developing an early-stage pipeline of gene therapy programs targeting other ocular diseases.
• The company has received Fast Track designation, PRIME designation, Innovation Passport and RMAT designation for Ixo-vec.
• The company has industry-leading development capabilities in AAV ocular gene therapy and AAV product optimization.
• The company has deep expertise developing and conducting clinical trials with a focus on regulatory compliance in the U.S and Europe.
• The company has gene therapy manufacturing expertise, specifically in scalable process development, assay development, and cGMP quality control.
• The company has a maturing portfolio of proprietary vectors with specific ocular cell tropism.
• The company has a robust patent portfolio.
• The company has an experienced leadership team with expertise in ophthalmology, gene therapy, manufacturing, drug development, regulatory approval, and commercialization.

Negatives

• There is substantial doubt about the company's ability to continue as a going concern.
• The company has incurred significant operating losses since inception and expects to incur significant losses for the foreseeable future.
• A material weakness in internal control over financial reporting was identified, leading to a restatement of prior financial statements.
• The company is subject to risks associated with subletting its leased premises, including risks associated with subtenant defaults.
• The company's business will depend substantially on the success of one or more of its product candidates.
• Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development.
• The occurrence of serious complications or side effects that outweigh the therapeutic benefit in connection with or during use of the company's product candidates could lead to discontinuation of the clinical development program.
• The results of nonclinical studies and early clinical trials are not always predictive of future results.
• If the company is unable to successfully develop and maintain robust and reliable manufacturing processes for its product candidates, it may be unable to advance clinical trials or licensure applications.
• Changes in methods of manufacturing or formulation of the company's product candidates may result in additional costs or delays.
• If the company is unable to produce sufficient quantities of its products and product candidates at acceptable costs, it may be unable to meet clinical or potential commercial demand.
• The company and its contractors are subject to significant regulation with respect to manufacturing and testing its product candidates.
• The company has relied, and expects to continue to rely, on third parties under contracts and partnerships to conduct some or all aspects of its research and development, and these third parties may not perform satisfactorily.
• The company will rely on third parties to conduct some nonclinical testing and all of its ongoing and planned clinical trials.
• The company's success depends on its ability to protect its intellectual property and its proprietary technologies.
• Claims by third parties that the company infringes their proprietary rights may result in liability for damages or prevent or delay its developmental and commercialization efforts.
• The company may not be successful in obtaining or maintaining necessary rights to its product candidates through acquisitions and in-licenses.
• The company's rights to develop and commercialize its product candidates are subject in part to the terms and conditions of licenses granted to it by other companies and universities.
• The patent protection and patent prosecution for some of the company's product candidates are dependent on third parties.
• The company may be subject to claims challenging the inventorship or ownership of its patents and other intellectual property.
• Third-party patent rights could delay or otherwise adversely affect the company's planned development and sale of product candidates of its programs.
• The company may not be able to obtain intellectual property rights or protect its intellectual property rights throughout the world.
• Changes in U.S. patent law could diminish the value of patents in general, thereby impairing the company's ability to protect its product candidates.
• If the company does not obtain patent term extensions for patents covering its product candidates, its business may be materially harmed.
• Any suspension of, or delays in the commencement or completion of, clinical trials for the company's product candidates could result in increased costs to the company, delay or limit its ability to generate revenue and adversely affect its commercial prospects.
• Final marketing approval for the company's product candidates by the FDA or other regulatory authorities outside the U.S. for commercial use may be delayed, limited or denied, any of which would adversely affect its ability to generate operating revenue.
• Even if the company receives regulatory approval, it still may not be able to successfully commercialize any of its product candidates, and the revenue that it generates from product sales, if any, could be limited.
• If the company's competitors develop treatments for the target indications of its product candidates that are approved, marketed more successfully, or demonstrated to be safer or more effective or easier to administer than its product candidates, its commercial opportunity will be reduced or eliminated.
• Even if the company obtains marketing approval for any of its product candidates, they could be subject to restrictions or withdrawal from the market, and it may be subject to penalties if it fails to comply with regulatory requirements or if it experiences unanticipated problems with its product candidates, when and if any of them are approved.
• Coverage and reimbursement may be limited or unavailable in certain market segments for the company's product candidates, which could make it difficult for it to sell its product candidates profitably.
• Healthcare and other reform legislation may increase the difficulty and cost for the company to obtain marketing approval of and commercialize its product candidates and, if approved, may affect the prices it may obtain.
• Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of the company's product candidates or adversely affect its ability to conduct its business or obtain marketing approvals for its product candidates.
• The company is dependent on the services of its key executives and clinical and scientific staff, and if it is not able to retain these members of its management or recruit additional management, clinical and scientific personnel, its business will suffer.
• The company may encounter difficulties in managing its growth and expanding its operations successfully.
• If the company's information technology systems or those third parties with whom it works, or its data, are or were compromised, it could experience adverse consequences resulting from such compromise.
• The trading price of the shares of the company's common stock has been and could continue to be highly volatile, and purchasers of its common stock could incur substantial losses.
• The company has identified a material weakness in its internal control over financial reporting.
• If the company is unable to remedy the material weakness, or if it fails to maintain an effective system of internal control over financial reporting in the future, it may not be able to accurately report its financial condition, results of operations or cash flows, which may adversely affect investor confidence in it and, as a result, the value of its common stock.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company's financial results are subject to fluctuations.
• The company's stock price is volatile.
• The company's internal controls are not effective.
• The company is subject to risks associated with subletting its leased premises, including risks associated with subtenant defaults.
• The company's business will depend substantially on the success of one or more of its product candidates.
• Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development.
• The occurrence of serious complications or side effects that outweigh the therapeutic benefit in connection with or during use of the company's product candidates could lead to discontinuation of the clinical development program.
• The results of nonclinical studies and early clinical trials are not always predictive of future results.
• If the company is unable to successfully develop and maintain robust and reliable manufacturing processes for its product candidates, it may be unable to advance clinical trials or licensure applications.
• Changes in methods of manufacturing or formulation of the company's product candidates may result in additional costs or delays.
• If the company is unable to produce sufficient quantities of its products and product candidates at acceptable costs, it may be unable to meet clinical or potential commercial demand.
• The company and its contractors are subject to significant regulation with respect to manufacturing and testing its product candidates.
• The company has relied, and expects to continue to rely, on third parties under contracts and partnerships to conduct some or all aspects of its research and development, and these third parties may not perform satisfactorily.
• The company will rely on third parties to conduct some nonclinical testing and all of its ongoing and planned clinical trials.
• The company's success depends on its ability to protect its intellectual property and its proprietary technologies.
• Claims by third parties that the company infringes their proprietary rights may result in liability for damages or prevent or delay its developmental and commercialization efforts.
• The company may not be successful in obtaining or maintaining necessary rights to its product candidates through acquisitions and in-licenses.
• The company's rights to develop and commercialize its product candidates are subject in part to the terms and conditions of licenses granted to it by other companies and universities.
• The patent protection and patent prosecution for some of the company's product candidates are dependent on third parties.
• The company may be subject to claims challenging the inventorship or ownership of its patents and other intellectual property.
• Third-party patent rights could delay or otherwise adversely affect the company's planned development and sale of product candidates of its programs.
• The company may not be able to obtain intellectual property rights or protect its intellectual property rights throughout the world.
• Changes in U.S. patent law could diminish the value of patents in general, thereby impairing the company's ability to protect its product candidates.
• If the company does not obtain patent term extensions for patents covering its product candidates, its business may be materially harmed.
• Any suspension of, or delays in the commencement or completion of, clinical trials for the company's product candidates could result in increased costs to the company, delay or limit its ability to generate revenue and adversely affect its commercial prospects.
• Final marketing approval for the company's product candidates by the FDA or other regulatory authorities outside the U.S. for commercial use may be delayed, limited or denied, any of which would adversely affect its ability to generate operating revenue.
• Even if the company receives regulatory approval, it still may not be able to successfully commercialize any of its product candidates, and the revenue that it generates from product sales, if any, could be limited.
• If the company's competitors develop treatments for the target indications of its product candidates that are approved, marketed more successfully, or demonstrated to be safer or more effective or easier to administer than its product candidates, its commercial opportunity will be reduced or eliminated.
• Even if the company obtains marketing approval for any of its product candidates, they could be subject to restrictions or withdrawal from the market, and it may be subject to penalties if it fails to comply with regulatory requirements or if it experiences unanticipated problems with its product candidates, when and if any of them are approved.
• Coverage and reimbursement may be limited or unavailable in certain market segments for the company's product candidates, which could make it difficult for it to sell its product candidates profitably.
• Healthcare and other reform legislation may increase the difficulty and cost for the company to obtain marketing approval of and commercialize its product candidates and, if approved, may affect the prices it may obtain.
• Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of the company's product candidates or adversely affect its ability to conduct its business or obtain marketing approvals for its product candidates.
• The company is dependent on the services of its key executives and clinical and scientific staff, and if it is not able to retain these members of its management or recruit additional management, clinical and scientific personnel, its business will suffer.
• The company may encounter difficulties in managing its growth and expanding its operations successfully.
• If the company's information technology systems or those third parties with whom it works, or its data, are or were compromised, it could experience adverse consequences resulting from such compromise.
• The trading price of the shares of the company's common stock has been and could continue to be highly volatile, and purchasers of its common stock could incur substantial losses.
• The company has identified a material weakness in its internal control over financial reporting.
• If the company is unable to remedy the material weakness, or if it fails to maintain an effective system of internal control over financial reporting in the future, it may not be able to accurately report its financial condition, results of operations or cash flows, which may adversely affect investor confidence in it and, as a result, the value of its common stock.

Future Outlook

The company expects to incur substantial expenditures in the foreseeable future for the development and potential commercialization of its product candidates and ongoing internal research and development programs.

Industry Context

The biopharmaceutical industry is characterized by intense competition to develop new proprietary technologies and therapies and a strong emphasis on intellectual property.

Comparison to Industry Standards

• Adverum's Ixo-vec gene therapy product candidate for wet AMD utilizes a proprietary vector, is administered through a single IVT injection, and will compete with a variety of therapies currently marketed and in development, including biologics, small molecules, long-acting delivery devices and gene therapy.
• Existing anti-VEGF therapies are well-established therapies and are widely accepted by physicians, patients and third-party payers as the standard-of-care treatment of patients with wet AMD.
• In the United States, most patients receive off-label bevacizumab, including as a first-line treatment.
• Many patients go on to receive Eylea, Eylea HD and Vabysmo (faricimab).
• There are several other companies in the U.S. or Europe with marketed products or products in development for the treatment of chronic retinal conditions that respond to anti-VEGF therapy, including wet AMD.
• These companies include 4D Molecular Therapeutics, AbbVie, Bayer, Clearside Biomedical, EyePoint Pharmaceuticals, Kodiak Sciences, Novartis, Ocular Therapeutix, Opthea, Outlook Therapeutics, Regeneron, REGENXBIO and Roche.

Corporate Governance

Legal Proceedings

• We terminated the sublease and initiated a lawsuit against the subtenant and Jaguar in the Superior Court of Wake County, North Carolina to enforce our rights under the sublease and to seek recovery of losses and damages due to the defaults by the subtenant and Jaguar.

Stakeholder Impact

• Stockholders may experience immediate dilution and, as a result, our stock price may decline.
• If we do not obtain additional financing and are required to terminate our operations, our stockholders will lose all or a part of their investment.
• If we are unable to retain our management, and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.

Next Steps

• Continue to follow subjects enrolled in the OPTIC three-year extension out to a total of five years.
• Continue to follow LUNA subjects for an additional four years, for a total of five years.
• We intend to initiate AQUARIUS, the second phase 3 trial of Ixo-vec in wet AMD, in the second half of 2025.

Key Dates

Keywords

Adverum Biotechnologies, Ixo-vec, wet AMD, gene therapy, clinical trials, financial results, risk factors, regulatory approval, manufacturing, intellectual property